Recently, the combination of TKIs, BCR/ABL kinase specific inhibitors, with induction and post-remission chemotherapy has significantly improved the long-term survival of ALL patients in CR [6]–[9]. Here, ABL1 is linked to acute lymphoblastic leukemia.